Guerbet : Hugues Lecat appointed Chairman of the Board of Directors of Guerbet.
24 Maio 2024 - 12:45PM
Guerbet : Hugues Lecat appointed Chairman of the Board of Directors
of Guerbet.
Hugues Lecat appointed Chairman of the
Board of Directors of Guerbet
Villepinte, 24 May
2024: Guerbet (FR0000032526 GBT), a
global specialist in contrast products and solutions for medical
imaging, is announcing the appointment of Hugues Lecat as Chairman
of the Board of Directors, in accordance with the previously
announced timetable (press release of 20 March 2024).
Following the approval of his appointment as
director at the Annual General Meeting held today at the registered
office, the Board of Directors of Guerbet unanimously decided to
appoint Hugues Lecat as Chairman of the Board of Directors, on the
recommendation of the Appointments and Remuneration Committee. This
dual appointment puts an end with immediate effect to his duties as
“censeur” (non-voting director) since 20 March 2024.
Didier Izabel will remain a director and
Chairman of the Audit Committee until the end of his term of office
in 2026.
“I would like to thank all the shareholders and
members of the Board of Directors of Guerbet, including Didier
Izabel, for their trust in me. I am particularly excited to be
given this role at a time when the Group is embarking on a
strategic acceleration on several fronts, in particular by
strengthening its leadership in MRI and bringing highly innovative
AI solutions to market. I will strive to contribute to this
acceleration by putting my expertise and deep passion for the
healthcare industry at the service of Guerbet,” said Hugues
Lecat.
Hugues Lecat is a graduate of the NEOMA business
school in Rouen and holds an MBA from INSEAD. He began his career
in the pharmaceutical sector at Medtronic France in the mid-1990s,
where he quickly demonstrated his skills in business development
and financial management. In 1999, Hugues moved to the commercial
operations arm of Aventis Pharma France, where he was Chief
Financial Officer for four years. He subsequently held several
senior management positions, including CEO of Théraplix, a
subsidiary of Aventis Pharma specialising in pain treatment and OTC
products, and CEO of Sanofi-Aventis OTC. In 2009, Hugues became CEO
of Cooper Consumer Health, before joining Ethypharm in 2010. As its
Chairman and CEO, Hugues transformed Ethypharm from its original
focus on galenic development into an international pharmaceutical
group focused on the central nervous system and injectable products
for hospitals. He has been Chairman of the Supervisory Board since
2019. Hugues was also a member of the Board of Directors of NOVASEP
on behalf of BPI between 2012 and 2017.
Guerbet’s Board of Directors is now composed of
12 members:
Hugues Lecat, Chairman of the Board, Independent
Director*
Pascale Auger, Independent
Director*
Carine Dagommer, Director
Marie De La Simone, Employee Director
Mark Fouquet, Director
Eric Guerbet, Director
Didier Izabel, Independent
Director*
Céline Lamort, Director
Nicolas Louvet, Director
Claire Massiot-Jouault, Director
Marc Massiot, Director
Jean-Sébastien Raynaud, Employee Director
*These 3 directors may be qualified as
independent members in accordance with the criteria of the
Afep-Medef Code.
Next event :
Publication of 1st half 2024 revenue 25
July 2024 after market close
About GuerbetAt Guerbet, we
build lasting relationships so that we enable people to live
better. That is our purpose. We are a leader in medical imaging
worldwide, offering a comprehensive range of pharmaceutical
products, medical devices, and digital and AI solutions for
diagnostic and interventional imaging. A pioneer in contrast media
for 97 years, with more than 2,920 employees worldwide, we
continuously innovate and devote 10% of our sales to research and
development in four centres in France, the United States and
Israel. Guerbet (GBT) is listed on Euronext Paris (segment B – mid
caps) and generated €786 million in revenue in 2023.
Contacts:
Guerbet Jérôme Estampes, Chief Financial
Officer +33 (0)1 45 91 50 00 / jerome.estampes@guerbet.comChristine
Allard, Head of Communications +33 (0)6 30 11 57 82 /
christine.allard@guerbet.com
ActifinMarianne Py, Financial Communications +33 (0)1 80 48 25
31 / marianne.py@seitosei-actifin.com Jennifer Jullia, Press +33
(0)1 56 88 11 19 / jennifer.jullia@seitosei-actifin.com
- 24 05-24 CP Conseil Administration Vdef EN
Guerbet (EU:GBT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Guerbet (EU:GBT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
